share_log

中银证券4月18日发布研报称，给予华东医药（000963.SZ）买入评级。评级理由主要包括：1）业绩保持稳健增长，坚持研发投入；2）医药工业板块业绩稳健增长，创新成果逐步兑现；3）医美业务保持高速增长，医美产品矩阵持续扩充。（每日经济新闻）

Bank of China Securities released a research report on April 18 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) maintaining steady growth in performance and maintaining investment in

Zhitong Finance ·  Apr 18 16:37
Bank of China Securities released a research report on April 18 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) maintaining steady growth in performance and maintaining investment in R&D; 2) the pharmaceutical industry sector's performance is growing steadily, and innovative results are gradually being realized; 3) the medical and aesthetic business has maintained rapid growth, and the medical and aesthetic product matrix continues to expand. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment